NEUP

Neuphoria Therapeutics Inc.

Nasdaq · Pharmaceutical Preparations · Inc. C3 · CIK 0001191070
$4.37 -2.67% $23.6M
Vol
Market Cap$23.6M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders7 funds
Inst. Value$1.2M
Inst. Activity2 buys / 0 sells
Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. C3·CIK 0001191070·Prev Close $4.49

Recent Activity

Inst.
RHUMBLINE ADVISERS — DOUBLED
202 shares ($783.00)
Inst.
MORGAN STANLEY — DOUBLED
58 shares ($225.00)
May 18, 2026 earnings_calendar
NEUP Q3 2026 Earnings Scheduled — 2026-05-18

Price Targets

$7.00 +40.6% upside Strong Buy
Current $4.98 Low $7.00 Median $7.00 High $7.00 1 analysts
$7.00 $7.00

Analyst Ratings

Strong Buy88% buy · 8 analysts
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
May 15, 2026 HC Wainwright & Co. DOWNGRADE Buy → Neutral

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-0.56 $-0.56 — $-0.56 90% YoY 1
Current FY $-4.07 $-4.07 — $-4.07 -1670% YoY 1
Next FY $-2.43 ▲ +36.8% $-2.43 — $-2.43 40% YoY 1

Top Institutional Holders

FundValueMove
BALYASNY ASSET MANAGEMENT L.P.$578.7K
VANGUARD CAPITAL MANAGEMENT LLC$401.0K
VANGUARD FIDUCIARY TRUST CO$136.7K
CITADEL ADVISORS LLC$78.7K
COMMONWEALTH EQUITY SERVICES, LLC$45.7K
7 institutional holders with $1.2M total value (305,101 shares) as of 2026-Q1. Top holders: BALYASNY, VANGUARD, VANGUARD.

Top Institutional Holders — 2026-Q1

#FundSharesValue% of TrackedLast Move
1BALYASNY ASSET MANAGEMENT L.P.142,183$578.7K46.6%
2VANGUARD CAPITAL MANAGEMENT LLC98,516$401.0K32.3%
3VANGUARD FIDUCIARY TRUST CO33,589$136.7K11.0%
4CITADEL ADVISORS LLC19,331$78.7K6.3%
5COMMONWEALTH EQUITY SERVICES, LLC11,222$45.7K3.7%
6RHUMBLINE ADVISERS202$822.000.1%DOUBLED +512.1%
7MORGAN STANLEY58$236.000.0%DOUBLED +728.6%

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
RHUMBLINE ADVISERSDOUBLED33202+512.1%$783.002025-Q4
MORGAN STANLEYDOUBLED758+728.6%$225.002025-Q4
BANK OF AMERICA CORP /DE/DOUBLED117+1600.0%$201.002025-Q3
RHUMBLINE ADVISERSNEAR_EXIT41533-92.0%$234.002025-Q2
RHUMBLINE ADVISERSTRIM1,106415-62.5%$2.4K2025-Q1

No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.

No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$7.00 mean target +40.6% upside Strong Buy (1.00)
$7.00 Low $7.00 High
MetricValue
Current Price$4.98
Target Low$7.00
Target Mean$7.00
Target Median$7.00
Target High$7.00
# Analysts1
RecommendationStrong Buy (1.00)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
$-0.56 $-0.56 $-0.56 89.9% +0.0% 0↑ 1↓ $0.0B 100.0% 1
Next Q
2026-09-30
$0.00 $0.00 $0.00 $0.0B 0.0%
Current FY
2026-06-30
$-4.07 $-4.07 $-4.07 -1669.6% +0.0% 0↑ 1↓ $0.0B -100.0% 1
Next FY
2027-06-30
$-2.43 $-2.43 $-2.43 40.3% +36.8% 0↑ 1↓ $0.0B 0.0% 1

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-0.560
7d ago$-0.560
30d ago$-0.560
60d ago$-0.560
90d ago$-0.560
1 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
May 15, 2026 HC Wainwright & Co. DOWNGRADE Buy Neutral

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20262510088%
May 1, 20262520078%
Apr 1, 20262520078%
Mar 1, 20262520078%
Feb 1, 20262520078%
Jan 1, 20262520078%
Strong BuyBuyHoldSellStrong Sell

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

May 18, 2026
earnings_calendar
NEUP Q3 2026 Earnings Scheduled — 2026-05-18